Evidence map›Paper›PMID 42095895›Full record

ArticleBlood2026

Jmjd1c-mediated epigenetic control of autoimmunity and HIT antibody production.

Mei Yu, Lu Zhou, Yongguang Zhang, Yongwei Zheng, Yuhong Chen, David W Wang, Nan Zhu, Renren Wen, Demin Wang

Abstract read
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mei YuVersiti Blood Research Institute, Milwaukee, WI.
Lu ZhouVersiti Blood Research Institute, Milwaukee, WI.
Yongguang ZhangVersiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0001-5459-1131
Yongwei ZhengVersiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0002-1947-5386
Yuhong ChenVersiti Blood Research Institute, Milwaukee, WI.
David W WangWashington University in St. Louis, St. Louis, MO.ORCID 0009-0007-4572-6955
Nan ZhuVersiti Blood Research Institute, Milwaukee, WI.
Renren WenVersiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0003-2420-8212
Demin WangVersiti Blood Research Institute, Milwaukee, WI.ORCID 0000-0001-5549-3795

Funding

The Immunobiology of Vaccine-induced Immune Thrombotic ThrombocytopeniaP01HL167668 · NHLBI · VERSITI WISCONSIN, INC. · PI Mortimer Poncz · 2024 to 2026
$10.1M
B cell responses in heparin-induced thrombocytopeniaR01HL130724 · NHLBI · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2017 to 2024
$4.8M
PLC?s in B cell biology and autoimmunityR01AI079087 · NIAID · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2008 to 2018
$4.4M
Molecular Basis of the Humoral Immune Response in Heparin-Induced ThrombocytopeniaR01HL148120 · NHLBI · VERSITI WISCONSIN, INC. · PI Renren Wen · 2019 to 2026
$3.8M
The histone demethylase JMJD1C in human Acute Myeloid LeukemiaR37CA229751 · NCI · VERSITI WISCONSIN, INC. · PI ZHU, NAN · 2019 to 2025
$2.9M
B-cell response and thrombotic complications in COVID-19R01HL161127 · NHLBI · VERSITI WISCONSIN, INC. · PI WEN, RENREN · 2022 to 2025
$2.6M
NCI NIH HHS R37 CA229751NHLBI NIH HHS P01 HL167668NHLBI NIH HHS R01 HL130724NHLBI NIH HHS R01 HL148120NHLBI NIH HHS R01 HL161127NIAID NIH HHS R01 AI079087
6 · The paper itself

Abstract

abstractHeparin-induced thrombocytopenia (HIT) is a common drug-induced immune disorder occurring in a subset of heparin-treated patients. Immune complexes comprising heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibodies are central to its pathogenesis. However, the role of epigenetic modification in HIT remains unexplored. Our study identified Jmjd1c, a member of the lysine-specific histone demethylase 3 subfamily, as an essential regulator of PF4/heparin-specific antibody production. Although Jmjd1c was expressed throughout B-cell development and was dispensable for normal B-cell development, its deficiency disrupted immune tolerance and promoted production of self-reactive antibodies in systemic autoimmune diseases, including PF4/heparin-specific platelet-activating antibodies, a hallmark of pathogenic HIT antibodies. Jmjd1c-deficient B cells were hyperresponsive, characterized by enhanced B-cell receptor (BCR)-induced proliferation. Transcriptomic analysis (RNA sequencing) revealed upregulation of pathways associated with BCR signaling, NF-κB activation, cell cycle, and systemic lupus erythematosus (SLE). CUT&Tag (cleavage under targets and tagmentation) profiling demonstrated that Jmjd1c deficiency increased H3K36me1 modification at gene start sites in these pathways, indicating that epigenetic dysregulation drives B-cell hyperactivation. Importantly, transcriptional profiling and regulon analysis of B cells from patients with HIT showed enrichment of BCR signaling, cell cycle, NF-κB, and SLE-associated pathways, closely mirroring those in Jmjd1c-deficient B cells. Epigenetic analyses further revealed enhanced promoter chromatin accessibility and elevated H3K36me1 deposition at promoter-transcription start site regions in HIT B cells. All these findings establish a strong molecular overlap between Jmjd1c deficiency and human HIT B cells and reveal a previously unrecognized epigenetic mechanism underlying HIT pathogenesis. To our knowledge, our study provides the first evidence linking epigenetic regulation to HIT, offering new insights into its pathophysiology.

Indexed as

AutoantibodiesAutoimmunityEpigenesis, GeneticJumonji Domain-Containing Histone DemethylasesAnimalsB-LymphocytesHumansMiceMice, KnockoutAutoantibodiesJumonji Domain-Containing Histone Demethylases

Identifiers

PMID42095895
PMCPMC13332704

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.